Do analysts prefer SILO or LPCN?

Lipocine has a consensus price target of $15.00, suggesting a potential upside of 610.90%. Given Lipocine's stronger consensus rating and higher probable upside, analysts plainly believe Lipocine is more favorable than Silo Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silo Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is SILO or LPCN more profitable?

Lipocine has a net margin of -755.39% compared to Silo Pharma's net margin of -6,726.39%. Lipocine's return on equity of -64.75% beat Silo Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Silo Pharma -6,726.39% -78.94% -63.86% Lipocine -755.39% -64.75% -57.62%

Does the media prefer SILO or LPCN?

In the previous week, Silo Pharma had 2 more articles in the media than Lipocine. MarketBeat recorded 4 mentions for Silo Pharma and 2 mentions for Lipocine. Lipocine's average media sentiment score of 1.31 beat Silo Pharma's score of 0.47 indicating that Lipocine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silo Pharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lipocine 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CYCN or SILO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Silo Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer SCNX or SILO?

Scienture currently has a consensus target price of $1.50, suggesting a potential upside of 221.96%. Given Scienture's stronger consensus rating and higher possible upside, research analysts clearly believe Scienture is more favorable than Silo Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scienture 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Silo Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SCNX or SILO more profitable?

Scienture has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. Scienture's return on equity of -51.84% beat Silo Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Scienture N/A -51.84% -42.22% Silo Pharma -6,726.39% -78.94% -63.86%

Does the media refer more to SCNX or SILO?

In the previous week, Scienture had 4 more articles in the media than Silo Pharma. MarketBeat recorded 8 mentions for Scienture and 4 mentions for Silo Pharma. Scienture's average media sentiment score of 0.99 beat Silo Pharma's score of 0.47 indicating that Scienture is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scienture 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Silo Pharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SILO or TVRD?

Tvardi Therapeutics has a consensus target price of $18.00, suggesting a potential upside of 847.37%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tvardi Therapeutics is more favorable than Silo Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silo Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tvardi Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Does the media prefer SILO or TVRD?

In the previous week, Tvardi Therapeutics had 1 more articles in the media than Silo Pharma. MarketBeat recorded 5 mentions for Tvardi Therapeutics and 4 mentions for Silo Pharma. Silo Pharma's average media sentiment score of 0.47 beat Tvardi Therapeutics' score of -0.03 indicating that Silo Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silo Pharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tvardi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SILO or BFRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silo Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is SILO or BFRI more profitable?

Biofrontera has a net margin of -13.78% compared to Silo Pharma's net margin of -6,726.39%. Silo Pharma's return on equity of -78.94% beat Biofrontera's return on equity. Company Net Margins Return on Equity Return on Assets Silo Pharma -6,726.39% -78.94% -63.86% Biofrontera -13.78% -155.98% -31.69%

Does the media prefer SILO or BFRI?

In the previous week, Biofrontera had 7 more articles in the media than Silo Pharma. MarketBeat recorded 11 mentions for Biofrontera and 4 mentions for Silo Pharma. Biofrontera's average media sentiment score of 0.75 beat Silo Pharma's score of 0.47 indicating that Biofrontera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silo Pharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biofrontera 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Silo Pharma (SILO) Competitors

$3.20 -0.02 (-0.62%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$3.20 -0.01 (-0.16%)

As of 08/14/2026 07:16 PM Eastern

Compare

SILO vs. LPCN, CYCN, SCNX, TVRD, and BFRI

Should you buy Silo Pharma stock or one of its competitors? Silo Pharma's main competitors and comparable companies include Lipocine (LPCN), Cyclerion Therapeutics (CYCN), Scienture (SCNX), Tvardi Therapeutics (TVRD), and Biofrontera (BFRI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Silo Pharma compare to Lipocine?

Silo Pharma (NASDAQ:SILO) and Lipocine (NASDAQ:LPCN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

5.6% of Silo Pharma shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 3.6% of Silo Pharma shares are owned by insiders. Comparatively, 4.7% of Lipocine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Silo Pharma has higher earnings, but lower revenue than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than Silo Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silo Pharma	$72.10K	55.61	-$4.23M	-$4.36	N/A
Lipocine	$1.98M	8.78	-$9.63M	-$1.79	N/A

Silo Pharma has a beta of 0.71, suggesting that its stock price is 29% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

Lipocine has a net margin of -755.39% compared to Silo Pharma's net margin of -6,726.39%. Lipocine's return on equity of -64.75% beat Silo Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silo Pharma	-6,726.39%	-78.94%	-63.86%
Lipocine	-755.39%	-64.75%	-57.62%

Lipocine has a consensus price target of $15.00, suggesting a potential upside of 610.90%. Given Lipocine's stronger consensus rating and higher probable upside, analysts plainly believe Lipocine is more favorable than Silo Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silo Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Silo Pharma had 2 more articles in the media than Lipocine. MarketBeat recorded 4 mentions for Silo Pharma and 2 mentions for Lipocine. Lipocine's average media sentiment score of 1.31 beat Silo Pharma's score of 0.47 indicating that Lipocine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silo Pharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lipocine	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lipocine beats Silo Pharma on 10 of the 15 factors compared between the two stocks.

How does Silo Pharma compare to Cyclerion Therapeutics?

Cyclerion Therapeutics (NASDAQ:CYCN) and Silo Pharma (NASDAQ:SILO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 5.6% of Silo Pharma shares are owned by institutional investors. 34.3% of Cyclerion Therapeutics shares are owned by company insiders. Comparatively, 3.6% of Silo Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cyclerion Therapeutics has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market. Comparatively, Silo Pharma has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market.

Cyclerion Therapeutics has a net margin of -170.11% compared to Silo Pharma's net margin of -6,726.39%. Silo Pharma's return on equity of -78.94% beat Cyclerion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%
Silo Pharma	-6,726.39%	-78.94%	-63.86%

Cyclerion Therapeutics has higher revenue and earnings than Silo Pharma. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Silo Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclerion Therapeutics	$2.07M	8.57	-$3.53M	-$1.66	N/A
Silo Pharma	$72.10K	55.61	-$4.23M	-$4.36	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Silo Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Silo Pharma had 3 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 4 mentions for Silo Pharma and 1 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.89 beat Silo Pharma's score of 0.47 indicating that Cyclerion Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cyclerion Therapeutics	Very Positive
Silo Pharma	Neutral

Summary

Cyclerion Therapeutics beats Silo Pharma on 8 of the 13 factors compared between the two stocks.

How does Silo Pharma compare to Scienture?

Scienture (NASDAQ:SCNX) and Silo Pharma (NASDAQ:SILO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Scienture has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. Scienture's return on equity of -51.84% beat Silo Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scienture	N/A	-51.84%	-42.22%
Silo Pharma	-6,726.39%	-78.94%	-63.86%

In the previous week, Scienture had 4 more articles in the media than Silo Pharma. MarketBeat recorded 8 mentions for Scienture and 4 mentions for Silo Pharma. Scienture's average media sentiment score of 0.99 beat Silo Pharma's score of 0.47 indicating that Scienture is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scienture	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Silo Pharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

5.7% of Scienture shares are owned by institutional investors. Comparatively, 5.6% of Silo Pharma shares are owned by institutional investors. 21.4% of Scienture shares are owned by insiders. Comparatively, 3.6% of Silo Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Scienture currently has a consensus target price of $1.50, suggesting a potential upside of 221.96%. Given Scienture's stronger consensus rating and higher possible upside, research analysts clearly believe Scienture is more favorable than Silo Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Silo Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Scienture has a beta of 3.26, indicating that its stock price is 226% more volatile than the broader market. Comparatively, Silo Pharma has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market.

Silo Pharma has lower revenue, but higher earnings than Scienture. Silo Pharma is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scienture	$430K	44.02	-$41.51M	-$2.10	N/A
Silo Pharma	$72.10K	55.61	-$4.23M	-$4.36	N/A

Summary

Scienture beats Silo Pharma on 14 of the 16 factors compared between the two stocks.

How does Silo Pharma compare to Tvardi Therapeutics?

Silo Pharma (NASDAQ:SILO) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Silo Pharma has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market.

5.6% of Silo Pharma shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 3.6% of Silo Pharma shares are held by company insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Tvardi Therapeutics has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. Tvardi Therapeutics' return on equity of -64.17% beat Silo Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silo Pharma	-6,726.39%	-78.94%	-63.86%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

Tvardi Therapeutics has a consensus target price of $18.00, suggesting a potential upside of 847.37%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tvardi Therapeutics is more favorable than Silo Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silo Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Silo Pharma has higher earnings, but lower revenue than Tvardi Therapeutics. Silo Pharma is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silo Pharma	$72.10K	55.61	-$4.23M	-$4.36	N/A
Tvardi Therapeutics	$7.14M	2.50	-$18.21M	-$3.10	N/A

In the previous week, Tvardi Therapeutics had 1 more articles in the media than Silo Pharma. MarketBeat recorded 5 mentions for Tvardi Therapeutics and 4 mentions for Silo Pharma. Silo Pharma's average media sentiment score of 0.47 beat Tvardi Therapeutics' score of -0.03 indicating that Silo Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silo Pharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tvardi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Tvardi Therapeutics beats Silo Pharma on 13 of the 17 factors compared between the two stocks.

How does Silo Pharma compare to Biofrontera?

Silo Pharma (NASDAQ:SILO) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Biofrontera has a net margin of -13.78% compared to Silo Pharma's net margin of -6,726.39%. Silo Pharma's return on equity of -78.94% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silo Pharma	-6,726.39%	-78.94%	-63.86%
Biofrontera	-13.78%	-155.98%	-31.69%

5.6% of Silo Pharma shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 3.6% of Silo Pharma shares are held by insiders. Comparatively, 8.1% of Biofrontera shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Silo Pharma has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market. Comparatively, Biofrontera has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

Silo Pharma has higher earnings, but lower revenue than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Silo Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silo Pharma	$72.10K	55.61	-$4.23M	-$4.36	N/A
Biofrontera	$43.20M	0.39	-$10.54M	-$0.45	N/A

In the previous week, Biofrontera had 7 more articles in the media than Silo Pharma. MarketBeat recorded 11 mentions for Biofrontera and 4 mentions for Silo Pharma. Biofrontera's average media sentiment score of 0.75 beat Silo Pharma's score of 0.47 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silo Pharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biofrontera	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silo Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Biofrontera beats Silo Pharma on 11 of the 15 factors compared between the two stocks.

Get Silo Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SILO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SILO vs. The Competition

Export

Metric	Silo Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.01M	$11.80B	$7.03B	$13.07B
Dividend Yield	N/A	2.70%	2.57%	10.64%
P/E Ratio	-0.73	779.99	271.26	25.40
Price / Sales	55.61	748.58	622.95	105.59
Price / Cash	N/A	89.04	75.70	53.27
Price / Book	0.45	11.60	12.92	6.21
Net Income	-$4.23M	$2.77B	$3.45B	$347.71M
7 Day Performance	-14.21%	0.14%	1.16%	1.08%
1 Month Performance	-33.05%	0.65%	2.17%	1.87%
1 Year Performance	-69.95%	145.68%	62.38%	20.79%

Silo Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SILO Silo Pharma	0.4423 of 5 stars	$3.20 -0.6%	N/A	-70.0%	$4.01M	$72.10K	N/A	2	Earnings Report
LPCN Lipocine	2.7797 of 5 stars	$2.06 -1.4%	$15.00 +628.2%	-30.4%	$17.23M	$1.98M	N/A	10	Positive News
CYCN Cyclerion Therapeutics	0.9849 of 5 stars	$3.92 +9.8%	N/A	+60.6%	$16.71M	$2.07M	N/A	30	Positive News High Trading Volume
SCNX Scienture	2.9859 of 5 stars	$0.45 +10.0%	$1.50 +233.3%	-61.5%	$16.62M	$430K	N/A	N/A	News Coverage Earnings Report Short Interest Decrease Gap Down High Trading Volume
TVRD Tvardi Therapeutics	3.6101 of 5 stars	$1.77 flat	$18.00 +916.9%	-92.1%	$16.60M	$7.14M	N/A	80	News Coverage Earnings Report Short Interest Decrease Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SILO) was last updated on 8/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silo Pharma (SILO) Competitors

SILO vs. LPCN, CYCN, SCNX, TVRD, and BFRI

How does Silo Pharma compare to Lipocine?

Summary

How does Silo Pharma compare to Cyclerion Therapeutics?

Summary

How does Silo Pharma compare to Scienture?

Summary

How does Silo Pharma compare to Tvardi Therapeutics?

Summary

How does Silo Pharma compare to Biofrontera?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SILO vs. The Competition

Silo Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silo Pharma (SILO) Competitors

SILO vs. LPCN, CYCN, SCNX, TVRD, and BFRI

How does Silo Pharma compare to Lipocine?

Do institutionals & insiders hold more shares of SILO or LPCN?

Which has preferable earnings & valuation, SILO or LPCN?

Which has more volatility and risk, SILO or LPCN?

Is SILO or LPCN more profitable?

Do analysts prefer SILO or LPCN?

Does the media prefer SILO or LPCN?

Summary

How does Silo Pharma compare to Cyclerion Therapeutics?

Do institutionals and insiders hold more shares of CYCN or SILO?

Which has more risk and volatility, CYCN or SILO?

Is CYCN or SILO more profitable?

Which has higher valuation and earnings, CYCN or SILO?

Do analysts prefer CYCN or SILO?

Does the media refer more to CYCN or SILO?

Summary

How does Silo Pharma compare to Scienture?

Is SCNX or SILO more profitable?

Does the media refer more to SCNX or SILO?

Do institutionals & insiders hold more shares of SCNX or SILO?

Do analysts prefer SCNX or SILO?

Which has more volatility and risk, SCNX or SILO?

Which has stronger earnings & valuation, SCNX or SILO?

Summary

How does Silo Pharma compare to Tvardi Therapeutics?

Which has more risk & volatility, SILO or TVRD?

Do institutionals and insiders believe in SILO or TVRD?

Is SILO or TVRD more profitable?

Do analysts rate SILO or TVRD?

Which has stronger valuation & earnings, SILO or TVRD?

Does the media prefer SILO or TVRD?

Summary

How does Silo Pharma compare to Biofrontera?

Is SILO or BFRI more profitable?

Do institutionals & insiders believe in SILO or BFRI?

Which has more risk and volatility, SILO or BFRI?

Which has better earnings and valuation, SILO or BFRI?

Does the media prefer SILO or BFRI?

Do analysts rate SILO or BFRI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SILO vs. The Competition

Silo Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools